Free tool
FAERS Monitor: Zepatier
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208261 or its brand name (Zepatier, Elbasvir, Grazoprevir). Reports on generic versions are filed under their own applications.
Reports
4,249
Serious
1,435
34% of reports
Hospitalization
575
Death reported
123
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue958
- headache756
- nausea558
- insomnia313
- diarrhoea256
- drug dose omission253
- vomiting182
- adverse event150
- pneumonia147
- hepatitis c137
- arthralgia133
- pruritus123
- dizziness122
- pain122
- joint swelling118
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 2 |
| 2016 | 656 |
| 2017 | 2,382 |
| 2018 | 684 |
| 2019 | 242 |
| 2020 | 79 |
| 2021 | 39 |
| 2022 | 30 |
| 2023 | 14 |
| 2024 | 69 |
| 2025 | 45 |
| 2026 | 7 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,910 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hepatitis cSignal | 137 | 56.8 | 48.1 | 7,375 |
| adverse eventSignal | 150 | 8.1 | 6.9 | 924 |
| drug dose omissionSignal | 253 | 7.6 | 6.7 | 1,449 |
| fatigueSignal | 958 | 6.1 | 5.8 | 4,229 |
| headacheSignal | 756 | 6.0 | 5.6 | 3,219 |
| insomniaSignal | 313 | 5.8 | 5.2 | 1,260 |
| joint swellingSignal | 118 | 4.8 | 4.1 | 358 |
| nauseaSignal | 558 | 3.5 | 3.2 | 1,028 |
| pneumoniaSignal | 147 | 2.2 | 1.9 | 102 |
| diarrhoea | 256 | 2.0 | 1.7 | 124 |
| vomiting | 182 | 1.9 | 1.7 | 81 |
| pruritus | 123 | 1.6 | 1.3 | 26 |
| arthralgia | 133 | 1.6 | 1.3 | 29 |
| dizziness | 122 | 1.2 | 1.0 | 4 |
| pain | 122 | 1.0 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.